parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in proximal tubule cells	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 55	0.85
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 7567

receipt 7576: CRLS1 in dopamine neurons, braak

power: full sample +0.04 (p 0.874, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.04 (p 0.888, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.03 (p 0.915, n 18). could be the mix.
skeptic: leave-one-out range -0.08 to +0.18, sign flips 5; without severely affected donors +0.04 (p 0.874, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CRLS1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 7575: CRLS1 in microglia, braak

power: full sample -0.15 (p 0.561, n 18), 95% CI -0.57 to +0.34. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.09 (p 0.722, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.14 (p 0.585, n 18). could be the mix.
skeptic: leave-one-out range -0.29 to -0.03, sign flips 0; without severely affected donors -0.15 (p 0.561, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CRLS1 in microglia.

case closed: nothing better to follow up.

loading the receipts